Guided Selection of Human Antibody Light Chains against TAG-72 Using a Phage Display Chain Shuffling Approach

다국어 초록 (Multilingual Abstract)

To enhance therapeutic potential of murine monoclonal antibody, humanization by CDR grafting is usually used to reduce immunogenic mouse residues. Most humanized antibodies still have mouse residues critical for antigen binding, but the mouse residues may evoke immune responses in humans. Previously, we constructed a new humanized version (AKA) of mouse CC49 antibody specific for tumor-associated glycoprotein, TAG-72. In this study, to select a completely human antibody light chain against TAG-72, guided selection strategy using phage display was used. The heavy chain variable region (VH) of AKA was used to guide the selection of a human TAG-72-specific light chain variable region (VL) from a human VL repertoire constructed from human PBL. Most of the selected VLs were identified to be originated from the members of the human germline VK1 family, whereas the VL of AKA is more homologous to the VK4 family. Competition binding assay of the selected Fabs with mouse CC49 suggested that the epitopes of the Fabs overlap with that of CC49. In addition, they showed better antigen-binding affinity compared to parental AKA. The selected human VLs may be used to guide the selection of human VHs to get completely human anti-TAG72 antibody.

참고문헌 (Reference)

1 Tamura, M, "Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only" 164 : 1432-1441, 2000

2 Divgi, C.R, "Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma" 1 : 1503-1510, 1995b

3 Mulligan, T, "Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma" 1 : 1447-1454, 1995

4 Divgi, C.R, "Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma" 36 : 586-592, 1995a

5 Pavlinkova, G, "Pharmacokinetics and biodistribution of a light-chainshuffled CC49 single-chain Fv antibody construct" 49 : 267-275, 2000

6 Figini, M, "Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection" 58 : 991-996, 1998

7 Kim, S.J, "Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display" 318 : 598-607, 2004

8 Gonzales, N.R, "Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues" 40 : 337-349, 2003

9 Marks, "In vitroassembly of repertoires of antibody chains on the surface ofphage by renaturation" 68-78, 1994

10 De Pascalis, R, "In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants" 9 : 5521-5531, 2003

11 Marks, "Humanantibodies from V-gene libraries displayed on phage" 581-597, 1991

12 A, "Guiding the selection of human antibodiesfrom phage display repertoires to a single epitope of an antigen" 899-903, 1994

13 Watzka, H, "Guided selection of antibody fragments specific for human interferon gamma receptor 1 from a human VH- and VL-gene repertoire" 3 : 279-291, 1998

14 Beiboer, S.H, "Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent" 296 : 833-849, 2000

15 Persson, "Generationof diverse high-affinity human monoclonal antibodies by repertoirecloning" 2432-88 2436, 1991

16 Kashmiri, S.V, "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49" 14 : 461-473, 1995

17 Thor, "Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72" 3118-3124, 1986

18 Yoon, S.O, "Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody" 281 : 6985-6992, 2006

19 A, "Clinical comparison of radiolocalizationof two monoclonal antibodies" 9-15, 1994

20 Iwahashi, M, "CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity" 36 : 1079-1091, 1999

21 Thor, "Adjunct to the diagnosticdistinction between adenocarcinomas of the ovary andthe colon utilizing a monoclonal antibody" 505-4 512, 1987

22 Burton, "A large array of humanmonoclonal antibodies to type 1 human immunodeficiency virusfrom combinatorial libraries of asymptomatic seropositiveindividuals" cha (cha): 10134-88 10137, 1991